Singapore markets closed

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4200+0.0100 (+0.71%)
At close: 04:00PM EDT
1.4000 -0.02 (-1.41%)
Pre-market: 09:17AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.4100
Bid1.3800 x 4000
Ask1.4000 x 800
Day's range1.3000 - 1.5400
52-week range0.5800 - 5.0000
Avg. volume12,836,200
Market cap205.162M
Beta (5Y monthly)0.43
PE ratio (TTM)N/A
EPS (TTM)-2.0840
Earnings date01 Nov 2022 - 07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.00
  • Motley Fool

    Why Clovis Oncology Stock Is Sinking Today

    Shares of the cancer drugmaker Clovis Oncology (NASDAQ: CLVS) are under pressure yet again today. After this latest dip, Clovis' stock is down by over 46% for the year. The biotech released its 2022 second-quarter earnings report ahead of the opening bell Monday morning, and its latest financial results aren't a hit with shareholders.

  • Zacks

    Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss

    Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.

  • Zacks

    Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates

    Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?